Meet the team
Providing Quality, Compassionate Care To Our Patients


We recognize the pandemic only served to exacerbate a system that was increasingly failing the needs of those with mental health issues as levels of anxiety and depression have soared. We believe our system has not kept pace with the increased demands that the population deserves.
Depression is the third leading cause of disability worldwide. Even if successfully treated, an estimated 80% of patients will experience relapse in the immediate years following remission and over 30% of patients experience treatment resistant depression. The FDA approved ketamine as a general anesthetic in 1970 and in the early 2000’s studies were conducted to investigate the success of ketamine as an antidepressant.
Drs. Girma, Woods, and Bloom have used ketamine in their daily emergency practice at much higher doses to achieve sedation for various procedures. We are well versed in the safety profile, side effects, and protocols to deliver ketamine harmlessly to our patients in the out-patient setting. As the medication has gained notoriety, we have witnessed inexperienced providers and companies that we believe do not have the appropriate oversight and proficiency to administer a schedule III medication.